KR960000232A - Antiperitoneal Adhesion Inhibitors in Humans and Animals Containing Sodium Up Carboxymethylcellulose and Dextran 70 - Google Patents

Antiperitoneal Adhesion Inhibitors in Humans and Animals Containing Sodium Up Carboxymethylcellulose and Dextran 70 Download PDF

Info

Publication number
KR960000232A
KR960000232A KR1019940013474A KR19940013474A KR960000232A KR 960000232 A KR960000232 A KR 960000232A KR 1019940013474 A KR1019940013474 A KR 1019940013474A KR 19940013474 A KR19940013474 A KR 19940013474A KR 960000232 A KR960000232 A KR 960000232A
Authority
KR
South Korea
Prior art keywords
dextran
humans
adhesion
abdominal
present
Prior art date
Application number
KR1019940013474A
Other languages
Korean (ko)
Other versions
KR0135707B1 (en
Inventor
이효종
Original Assignee
이효종
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이효종 filed Critical 이효종
Priority to KR1019940013474A priority Critical patent/KR0135707B1/en
Publication of KR960000232A publication Critical patent/KR960000232A/en
Application granted granted Critical
Publication of KR0135707B1 publication Critical patent/KR0135707B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

사람 및 동물에서 복강장기의 치료 및 진단을 위한 개복수술, 복강경시술, 수정란 이식, 복강장기의 손상 및 복막염 등으로 흔히 발생하는 후유증 중의 하나는 복강장기의 유착형성이다. 복강장기의 유착은 복통, 소화장애, 기능장해, 불임 등 그 피해가 막대하여 이를 방지하고자 본 발명이 고안되었다. 유착방지 목적으로 사용하고 있는 기존 약제들은 그 효능이 낮거나 불명확하고, 폐사율의 증가, 출혈, 면역기능의 저하, 체중감소, 착상방해 및 운동성 저하 등의 부작용이 보고되어 왔다. 본 발명은 sodium carboxymethylcellulose 및 dextran 70을 생리식염수에 각각 1% 및 10% 혼합하여 합제를 만들고 멸균처리한 다음 공장에 찰과상을 일으킨 토끼의 복강내에 체중 ㎏당 5㎖을 투여하였던 바 매우 높은 유착방지 효능능 나타내었다. 나아가서 본 발명을 주입한 다음 1,3,5일 및 4주일후에 이들 토끼로 부터 혈액을 채취하여 혈액내의 총백혈구수, 임파구수, 적혈구수, 혈장섬유소원, 적혈구용적, 혈장단백질 농도 등을 조사하였던 바 대조군보다 변동이 적었으며 주목할만한 부작용을 보이지 않았다. 그리고 수술 4주일후에 체중의 변화를 조사하였던 바 대조군에 비하여 체중감소가 적었다. 그러므로 사람 및 동물의 복강장기 유착을 방지할 목적으로 본 발명인 수성 부형제에 sodium carboxymethylcellulose가 1% 함유되고 dextran 70이 10% 함유되게 조성하여 투여하는 것이 매우 효과적이며 부작용이 적을 것으로 판단된다.One of the most common sequelae of laparotomy, laparoscopy, fertilized egg transplant, peritoneal injuries and peritonitis, etc. for the treatment and diagnosis of intraperitoneal organs in humans and animals is adhesion formation of the abdominal organs. The adhesion of the abdominal organs has been devised to prevent the damage such as abdominal pain, digestive disorders, dysfunction, infertility is enormous. Existing drugs that are used for the purpose of preventing adhesion have low or unclear effects, and side effects such as increased mortality, bleeding, decreased immune function, weight loss, impaired implantation, and reduced mobility have been reported. In the present invention, sodium carboxymethylcellulose and dextran 70 were mixed with 1% and 10% of physiological saline, respectively, to make a mixture and sterilized, and then 5 ml per kilogram of body weight in the abdominal cavity of rabbits which caused abrasions was very high. It is shown. Furthermore, blood was collected from these rabbits 1, 3, 5 and 4 weeks after the present invention was injected to investigate the total leukocyte count, lymphocyte count, erythrocyte count, plasma fibrinogen, erythrocyte volume, and plasma protein concentration in the blood. It was less volatile than the bar control and showed no noticeable side effects. After 4 weeks of surgery, the weight change was less than that of the control group. Therefore, in order to prevent intraperitoneal adhesions of humans and animals, it is determined that the composition of the aqueous excipient of the present invention contains 1% sodium carboxymethylcellulose and 10% dextran 70.

Description

소디엄 카복시메틸셀루로즈(sodium carboxymethylcellulose)와 덱스트란 70(dextran 70)을 함유한 사람 및 동물의 복강장기 유착방지제Antiperitoneal Adhesion Inhibitors in Humans and Animals Containing Sodium Carboxymethylcellulose and Dextran 70

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (1)

사람 및 동물의 복강용으로 허용되는 생리식염수 또는 수성 부형제에 SCMC 1%와 dextran 70 10%를 함유한 조성물.A composition containing 1% SCMC and 10% dextran 70 in physiological saline or aqueous excipients that are acceptable for human and animal abdominal cavity. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940013474A 1994-06-13 1994-06-13 Preventing agents for adhesion of human or animals KR0135707B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940013474A KR0135707B1 (en) 1994-06-13 1994-06-13 Preventing agents for adhesion of human or animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940013474A KR0135707B1 (en) 1994-06-13 1994-06-13 Preventing agents for adhesion of human or animals

Publications (2)

Publication Number Publication Date
KR960000232A true KR960000232A (en) 1996-01-25
KR0135707B1 KR0135707B1 (en) 1998-04-23

Family

ID=19385320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940013474A KR0135707B1 (en) 1994-06-13 1994-06-13 Preventing agents for adhesion of human or animals

Country Status (1)

Country Link
KR (1) KR0135707B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030055102A (en) * 2001-12-26 2003-07-02 (주)아미티에 An Antiadhesion Barrier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030055102A (en) * 2001-12-26 2003-07-02 (주)아미티에 An Antiadhesion Barrier

Also Published As

Publication number Publication date
KR0135707B1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
EP0139535B1 (en) Compositions for combatting toxaemia
KR920019342A (en) Bone Disease Treatment
BR0314943A (en) Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These
KR970706830A (en) COMPOSITION OF CISPLATIN IN COMBINATION WITH 2, 2'-DITHIO-BIS (ETHANESULFONATE) (DIMESNA)
RU93054168A (en) DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS
BR0013065A (en) Method and compound to treat a disease associated with aberrant leukocyte recruitment and / or activation
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
EA199900499A1 (en) PHARMACEUTICAL COMPOSITION, INCLUDING A COMPOUND, OWNED ANTI-XA ACTIVITY, AND CONNECTION ANTAGONIST OF PLATELET AGGREGATION
ES2109260T3 (en) TRANSFORMED Erythrocytes, PROCEDURE TO PREPARE THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS.
DE68929388D1 (en) Anticoagulant compound isolated from urine
Pietrogrande et al. Short-term evaluation of synovectomy in haemophilia
Vollum et al. Livedo reticularis during amantadine treatment
Hawking Prevention of gas-gangrene infections by local application of sulphonamide compounds and by sera
KR960000232A (en) Antiperitoneal Adhesion Inhibitors in Humans and Animals Containing Sodium Up Carboxymethylcellulose and Dextran 70
Galland et al. Nonspecific stimulation of host defenses against bacterial challenge in immunosuppressed mice
KR100266929B1 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
JPH06340549A (en) Therapeutic agent for feline respiratory organ disease and therapeutic method using the therapeutic agent
Sheehy et al. Treatment of sickle cell disease
AU704517B2 (en) Anti-piroplasmotic agent
Rodriguez et al. Successful enteral refeeding after massive small bowel resection.
JPH08782B2 (en) Anti-inflammatory agent
Schattner et al. Fulminant streptococcal myositis
RU2056844C1 (en) Agent having anticombustion action
CA2120917A1 (en) External preparation for treating hemorrhoidal diseases
Feng et al. Soft-tissue infection in lower extremity trauma

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee